Clinical trial Recruiting at 1 site Observational Ages 50 and up

Diabetes, Dementia, and Oxidative Stress: A look at Nox2-related markers

Official title: Cardiovascular And Dementia Risk in diabeTes Experimental and Clinical Study: Investigation on Nox2- Related Oxidative Stress (CARTESIO).

Run by Neuromed IRCCS · NCT07928453 · Data updated 2026-11-12

This study tests whether oxidative stress linked to Nox2 is related to dementia risk in adults with type 2 diabetes.

More Dementia trials

Quick facts

Study typeObservational
Ages50 Years and up
SexAll
Enrollment250 (estimated)
SponsorNeuromed IRCCS
Academic / other
Drugs / interventionschemotherapy, radiation
Locations1 site (Pozzilli)
StatusRecruiting
StartedAugust 31, 2024
Main results expectedJanuary 2027
Study endsFebruary 28, 2027
Registry record updatedNovember 10, 2026
Trial IDNCT07928453 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults over 50 with established type 2 diabetes, who are either treatment-naive or on one or two oral antidiabetic drugs, and who can provide informed consent.

Probably not a fit

Patients with recent acute diabetes complications, very high HbA1c, or recent major cardiovascular events may not benefit from participation.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study explores the connection between diabetes, oxidative stress, and dementia risk by examining Nox2-related markers in adults with type 2 diabetes. Participants are adults over 50 with established T2D who meet specific medication and health criteria. The research looks at how oxidative stress might link diabetes duration and vascular or neurodegenerative outcomes, using biomarkers and health data collected under real-world conditions. It is not a treatment trial and does not assign experimental therapies. Findings could clarify potential mechanisms and identify biomarkers for dementia risk in diabetes.

Why it matters

Potential benefit: If successful, the study could help identify biomarkers associated with higher dementia risk in people with diabetes.

How similar studies have gone: Previous work has linked oxidative stress and diabetes to cognitive decline, but this study aims to specifically relate Nox2-related oxidative stress to dementia risk in a diabetes population.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Established diagnosis of T2D according to the 2019 ESC guidelines
* Written informed consent obtained from the patient before enrollment
* Antidiabetic drug-naive, or treated with one or two oral anti-diabetic drugs, or treated with human NPH insulin or longacting insulin analogue or pre-mixed insulin, alone or in combination with one or two oral anti-diabetic drugs
* Age \>50 years

Exclusion Criteria:

* \- Acute decompensation of glycaemic control requiring immediate intensification of treatment to prevent acute complications of diabetes (eg diabetes ketoacidosis) within 90 days prior to screening
* HbA1c \>10%
* History of chronic pancreatitis or idiopathic acute pancreatitis
* History of ischemic stroke or transient ischemic attack
* Acute coronary event within 30 days before enrolment
* Currently planned coronary, carotid or peripheral artery revascularization
* Chronic Heart Failure NYHA Class IV
* End-stage liver disease, defined as the presence of acute or chronic liver disease and recent history of one or more of the following: ascites, encephalopathy, variceal bleeding, bilirubin \>2.0 mg/dL, albumin level \<3.5 g/dL, prothrombin time \>4 seconds prolonged, international normalised ratio (INR) \>1.7 or prior liver transplant
* End-stage chronic kidney disease (eGFR \<30 ml/min)
* Malignant neoplasm requiring chemotherapy, surgery, radiation or palliative therapy in the previous 5 years
* Life expectancy \<2 years (and in any case before the completion of the study)
* Low adherence to prescribed medications
* Female of childbearing potential who is pregnant, breast-feeding or intend to become pregnant or is not using adequate contraceptive methods
* Use of oral anticoagulants (atrial fibrillation of venous thromboembolism)

Where it's running

  • Neuromed Irccs
    Pozzilli, Italy
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.